Journal
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY
Volume 8, Issue 1, Pages 55-66Publisher
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.4251/wjgo.v8.i1.55
Keywords
Pancreatic cancer; Molecular characterization; Targeted therapy; Epidermal growth factor receptor inhibitors; Embryonic pathway inhibitors; Antiangiogenic therapies
Categories
Ask authors/readers for more resources
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies with a five-year survival rate of approximately 5%. Several target agents have been tested in PDAC, but almost all have failed to demonstrate efficacy in late phase clinical trials, despite the better understanding of PDAC molecular biology generated by large cancer sequencing initiatives in the past decade. Eroltinib (a small-molecule tyrosine-kinase inhibitor of epidermal growth factor receptor) plus gemcitabine is the only schedule with a biological agent approved for advanced pancreatic cancer, but it has resulted in a very modest survival benefit in unselected patients. In our work, we report a summary of the main clinical trials (closed and ongoing) that refer to biological therapy evaluation in pancreatic cancer treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available